C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2026)

C4 Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 47.67% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was -$2.8 million, a 750.6% decrease from a year earlier, with the FY2025 full-year figure at -$6.0 million, down 377.43% from the prior year.
• Change in Accured Expenses fell to -$3.5 million in Q1 2026 per CCCC's latest filing, from $2.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.2 million in Q4 2023 and bottomed at -$7.7 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $537000.0 (2023), against an average of -$261117.6.
• Biggest YoY gain for Change in Accured Expenses was 669.17% in 2024; the steepest drop was 426.07% in 2024.
• Year by year, Change in Accured Expenses stood at $2.7 million in 2022, then surged by 92.5% to $5.2 million in 2023, then fell by 23.29% to $4.0 million in 2024, then tumbled by 47.95% to $2.1 million in 2025, then sank by 270.23% to -$3.5 million in 2026.
• Per Business Quant, the three latest CCCC Change in Accured Expenses figures stand at -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and -$2.0 million (Q3 2025).